RNAi技術市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、應用、最終用戶、地區和競爭格局分類，2021-2031年

全球 RNAi 技術市場預計將從 2025 年的 16.1 億美元成長到 2031 年的 29.9 億美元，複合年成長率達到 10.87%。

該領域涵蓋了透過RNA干擾機制中和特定mRNA分子並抑制基因表現來治療遺傳性疾病、病毒感染疾病和惡性腫瘤的研究工具和療法。市場成長的主要驅動力是慢性病發病率的上升以及對精準醫療（能夠治療以往無法治癒的疾病）的迫切需求。此外，藥物遞送系統（尤其是脂質奈米顆粒製劑）的不斷進步，正在提高這些療法的穩定性和生物利用度，從而促進其在臨床實踐中的更廣泛應用。

儘管取得了這些進展，但將RNA分子遞送至肝臟以外的組織仍然十分複雜，這仍然是限制這些技術目前治療範圍的主要障礙。開發能夠確保RNA分子在血液中穩定性並促進細胞內吸收且不引發脫靶免疫反應的解決方案，持續增加研發的難度。然而，正如美國基因與細胞治療學會（ASGCT）的數據所示，業界仍在努力克服這些轉化挑戰。 2025年第二季度，啟動了38項新的臨床試驗，顯著擴展了RNA療法的研發管線。這表明業界仍在持續投入，以應對這些挑戰。

市場促進因素

癌症和慢性感染疾病率的上升是全球RNAi技術市場成長的主要驅動力。傳統治療方法往往難以應對複雜的遺傳因素，而RNA干擾技術提供了一種獨特的機制，能夠高精度地沉默特定的疾病相關基因。日益加重的疾病負擔凸顯了這項迫切需求。美國癌症協會發布的《2025年癌症事實與數據》報告預測，2025年，美國將新增超過200萬例癌症病例。因此，RNAi療法能夠針對以往「無法治療」的靶點，這使其成為未來腫瘤和感染疾病治療方法中不可或缺的一部分。

同時，生命科學領域的策略合作和授權協議正透過提供推動臨床研發所需的資金來加速市場擴張。領先的製藥公司正擴大與專業的生物技術公司合作，以利用其專有平台並降低研發風險。例如，正如GeneOnline在2025年9月報導的那樣，諾華公司向其與Argo Biopharma的合作追加投資52億美元，以推進用於治療心血管疾病的RNAi療法的研發。這些合作有效地將研發與商業性成果聯繫起來，作為這項進展的佐證，Arrowhead Pharmaceuticals在2025年宣布，其用於治療遺傳性乳糜微粒血症症候群的新型RNAi療法prozasilan已獲得美國FDA核准。

市場挑戰

將RNA分子高效率地遞送至肝臟以外的其他組織是限制全球RNAi技術市場擴張的主要障礙。儘管現有技術在靶向肝臟方面已取得成功，但如何開發能夠到達大腦、心臟和肺部等器官且不引起分解或毒性的遞送方法，嚴重限制了市場發展。這項技術限制使得RNAi療法的商業性應用範圍僅限於少數適應症，從而有效地限制了目標市場，並阻礙了其進入神經病學和廣譜腫瘤學等高需求治療領域。

因此，確保藥物在血液中的穩定性並防止脫靶免疫反應的複雜性，給藥物研發過程帶來了巨大的阻力。這些轉化障礙增加了新藥候選者的風險，導致研發週期延長，臨床試驗也需要更加謹慎。這些障礙的影響在近期的產業指標中顯而易見。根據美國基因與細胞治療學會（ASGCT）的數據，2025年第三季基因、細胞和RNA療法的臨床研發活動整體放緩，新啟動的臨床實驗數量在經歷了上一季的大幅成長後，降至125項。這項萎縮凸顯了與遞送技術相關的難題如何直接阻礙了研發管線的進展，並延緩了市場成熟。

市場趨勢

基於RNAi的生物農藥和農業解決方案的商業化，正從根本上拓展市場，使其不再局限於人類治療領域，而是應用於作物保護的關鍵挑戰。這一趨勢利用RNA干擾的特異性，在不損害永續或環境的前提下，沉默害蟲體內的關鍵基因，從而為傳統的化學藥劑提供了一種永續的替代方案。產業相關人員正在加速資金籌措，以推動這些環境友善平台從實驗室走向田間試驗。例如，Renaissance BioScience公司於2025年9月宣布，已獲得加拿大政府83萬加元的資金籌措，用於加速其專有的RNAi生物防治技術在農業領域的應用開發。

同時，支持RNAi療法大規模生產的結構性變革之一是對合約研發生產機構（CDMO）在可擴展寡核苷酸生產方面的依賴性日益增強。隨著研發管線擴展到高頻疾病領域，研發公司正將生產外包給擁有先進製造能力和商業規模所需監管專業知識的專業機構。這種策略性外包使製藥公司能夠降低技術製造風險，並加快為大規模的患者群體建立供應鏈。為了支持這項擴張，Bachem在2025年7月報告稱，該公司在上半年投資了1.291億瑞士法郎，重點用於擴大其全球生產網路的產能。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球RNAi技術市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 按類型（微型RNA、小干擾RNA、其他）
  • 依應用領域（治療類型、治療藥物、藥物傳遞、農業、其他）
  • 按最終用戶（研究和學術機構、診斷實驗室等）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美RNAi技術市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲RNAi技術市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區RNAi技術市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲RNAi技術市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美RNAi技術市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球RNAi技術市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Alnylam Pharmaceuticals, Inc
• Ionis Pharmaceuticals, Inc.
• Atalanta Therapeutics Inc.
• Phio Pharmaceuticals Corp.
• Benitec Biopharma Ltd.
• Novartis AG
• AstraZeneca PLC
• Silence Therapeutics Plc.
• Arbutus Biopharma Corp.
• Sylentis SA

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global RNAi Technology Market is projected to expand from USD 1.61 Billion in 2025 to USD 2.99 Billion by 2031, achieving a compound annual growth rate of 10.87%. This sector encompasses both research tools and therapeutics that employ RNA interference mechanisms to neutralize specific mRNA molecules, thereby inhibiting gene expression to address genetic disorders, viral infections, and malignancies. The market's growth is primarily driven by the increasing incidence of chronic diseases and the surging demand for precision medicine capable of treating targets that were previously considered undruggable. Furthermore, continuous advancements in drug delivery systems, particularly lipid nanoparticle formulations, are improving the stability and bioavailability of these therapeutics, which facilitates their broader clinical adoption.

Despite these advances, the complexity of delivering RNA molecules to tissues outside the liver presents a significant obstacle that limits the current therapeutic reach of these technologies. Developing solutions that ensure stability within the bloodstream and facilitate cellular uptake without provoking off-target immune reactions continues to complicate development timelines. However, the industry remains committed to overcoming these translational hurdles, as evidenced by data from the American Society of Gene & Cell Therapy; in the second quarter of 2025, the RNA therapy pipeline grew significantly with the initiation of 38 new clinical trials, signaling persistent investment in addressing these challenges.

Market Driver

The escalating prevalence of cancer and chronic infectious diseases acts as a primary engine for growth in the Global RNAi Technology Market. Because conventional therapeutic modalities frequently struggle to address complex genetic drivers, RNA interference offers a unique mechanism for silencing specific disease-causing genes with high precision. This critical need is highlighted by the rising disease burden; the American Cancer Society's "Cancer Facts & Figures 2025" report projected that more than 2 million new cancer cases would be diagnosed in the United States in 2025. Consequently, the ability of RNAi therapeutics to engage targets previously deemed undruggable positions them as essential components of future treatment regimens for oncology and infectious diseases.

Simultaneously, strategic collaborations and licensing agreements within the life sciences sector are accelerating market expansion by providing the necessary capital to advance clinical pipelines. Leading pharmaceutical companies are increasingly partnering with specialized biotech firms to utilize proprietary platforms and mitigate development risks. For example, GeneOnline reported in September 2025 that Novartis committed an additional $5.2 billion to its collaboration with Argo Biopharma to develop RNAi therapies for cardiovascular conditions. These alliances are effectively translating research and development into commercial reality; underscoring this progress, Arrowhead Pharmaceuticals announced in 2025 that the U.S. FDA approved plozasiran, a novel RNAi therapeutic for familial chylomicronemia syndrome.

Market Challenge

The difficulty of efficiently delivering RNA molecules to tissues beyond the liver constitutes a formidable barrier that hampers the expansion of the Global RNAi Technology Market. Although current technologies have proven successful for hepatic targets, the market is severely constrained by the challenge of engineering delivery vehicles capable of navigating to organs such as the brain, heart, or lungs without degrading or causing toxicity. This technical limitation confines the commercial scope of RNAi therapeutics to a narrow range of indications, effectively capping the addressable market and preventing entry into high-demand therapeutic areas like neurology and broad-spectrum oncology.

Consequently, the complexity of ensuring bloodstream stability and preventing off-target immune responses has introduced significant friction into the drug development process. These translational obstacles increase the risk profile of new candidates, leading to extended development timelines and a more cautious approach to clinical progression. The impact of these barriers is evident in recent industry metrics; according to the American Society of Gene & Cell Therapy, clinical development activity slowed across the broader gene, cell, and RNA landscape in the third quarter of 2025, with total trial initiations falling to 125 after a surge in the previous quarter. This contraction highlights how delivery-related difficulties directly throttle the pipeline's velocity and delay market maturation.

Market Trends

The commercialization of RNAi-based biopesticides and agricultural solutions is fundamentally diversifying the market beyond human therapeutics by addressing critical challenges in crop protection. This trend utilizes the specificity of RNA interference to silence essential genes in pests without harming beneficial insects or the environment, offering a sustainable alternative to conventional chemical agents. Industry players are increasingly securing capital to advance these eco-friendly platforms from the laboratory to field trials; for instance, Renaissance BioScience announced in September 2025 that it secured CAN$830,000 in funding from the Government of Canada to accelerate the development of its proprietary RNAi biocontrol technology for the agriculture sector.

Concurrently, an increasing reliance on Contract Development and Manufacturing Organizations (CDMOs) for scalable oligonucleotide manufacturing is emerging as a structural shift to support the mass production of RNAi therapeutics. As the pipeline expands into high-prevalence indications, developers are externalizing production to specialized organizations that offer the advanced capacity and regulatory expertise required for commercial volumes. This strategic outsourcing allows pharmaceutical firms to mitigate technical manufacturing risks and accelerate supply chain readiness for large-scale patient populations. Underscoring this expansion, Bachem reported in July 2025 that it invested CHF 129.1 million in the first half of the year specifically to expand production capacity across its global site network.

Key Market Players

• Alnylam Pharmaceuticals, Inc
• Ionis Pharmaceuticals, Inc.
• Atalanta Therapeutics Inc.
• Phio Pharmaceuticals Corp.
• Benitec Biopharma Ltd.
• Novartis AG
• AstraZeneca PLC
• Silence Therapeutics Plc.
• Arbutus Biopharma Corp.
• Sylentis S.A.

Report Scope

In this report, the Global RNAi Technology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

RNAi Technology Market, By Type

• Micro RNA
• Small interfering RNA
• Others

RNAi Technology Market, By Application

• Treatment Type
• Therapeutics
• Drug Delivery
• Agriculture
• Others

RNAi Technology Market, By End User

• Research and Academic Laboratories
• Diagnostic Laboratories
• Others

RNAi Technology Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global RNAi Technology Market.

Available Customizations:

Global RNAi Technology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global RNAi Technology Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Micro RNA, Small interfering RNA, Others)
  • 5.2.2. By Application (Treatment Type, Therapeutics, Drug Delivery, Agriculture, Others)
  • 5.2.3. By End User (Research and Academic Laboratories, Diagnostic Laboratories, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America RNAi Technology Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States RNAi Technology Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada RNAi Technology Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico RNAi Technology Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe RNAi Technology Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany RNAi Technology Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France RNAi Technology Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom RNAi Technology Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy RNAi Technology Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain RNAi Technology Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific RNAi Technology Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China RNAi Technology Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India RNAi Technology Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan RNAi Technology Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea RNAi Technology Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia RNAi Technology Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa RNAi Technology Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia RNAi Technology Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE RNAi Technology Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa RNAi Technology Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America RNAi Technology Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil RNAi Technology Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia RNAi Technology Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina RNAi Technology Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global RNAi Technology Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Alnylam Pharmaceuticals, Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Ionis Pharmaceuticals, Inc.
• 15.3. Atalanta Therapeutics Inc.
• 15.4. Phio Pharmaceuticals Corp.
• 15.5. Benitec Biopharma Ltd.
• 15.6. Novartis AG
• 15.7. AstraZeneca PLC
• 15.8. Silence Therapeutics Plc.
• 15.9. Arbutus Biopharma Corp.
• 15.10. Sylentis S.A.

16. Strategic Recommendations

17. About Us & Disclaimer